한글목차

최근 전문의 약품 시장 규모는 두드러진 성장세를 보이고 있습니다. 2025년 5,940억 5,000만 달러에서 2026년에는 6,531억 6,000만 달러에 이르고, CAGR 10.0%의 성장이 전망되고 있습니다. 지난 수년간의 성장은 전문 의약품의 높은 비용, 첨단 치료법의 제한된 가용성, 만성질환 및 희귀질환의 유병률 증가, 의료 인프라 확충, 전문치료에 대한 환자 인식 증가 등이 주요 요인으로 꼽힙니다.

특수 의약품 시장 규모는 향후 몇 년간 강력한 성장이 전망됩니다. 2030년에는 9,433억 1,000만 달러에 이르고, CAGR은 9.6%를 나타낼 전망입니다. 예측 기간 동안의 성장은 세포 및 유전자 치료제 개발, 개인 맞춤형 의료의 확대, 생물학적 제제 및 바이오시밀러에 대한 투자 증가, 첨단 약물 전달 시스템의 채택 확대, 원격 의료 및 원격 환자 관리의 성장에 기인할 것으로 보입니다. 예측 기간 동안 주요 동향으로는 전문 치료 분야에서 생물학적 제제 및 바이오시밀러의 채택 증가, 희귀질환을 위한 희귀의약품의 성장, 개인 맞춤형 의료 및 첨단 약물 전달 시스템 활용 확대, 만성질환 관리를 위한 재택의료 및 전문 클리닉의 확대, 전문 의약품을 위한 원격의료 및 원격 환자 모니터링의 통합 등이 있습니다. 전문 의약품을 위한 원격의료와 원격 환자 모니터링의 통합 등을 들 수 있습니다.

향후 몇 년 동안 만성질환의 유병률 증가가 전문의약품 시장의 성장을 견인할 것으로 예측됩니다. 만성질환은 보통 1년 이상 지속되는 장기적인 건강상태를 의미하며, 지속적인 치료가 필요하고 일상생활에 제한을 가져오는 경우가 많습니다. 만성질환의 유병률 증가는 주로 고령화에 기인하며, 고령층은 당뇨병, 심장병, 관절염 등의 질병에 걸리기 쉽습니다. 전문의약품은 특히 표준치료가 불충분한 경우, 환자의 치료 성과와 삶의 질을 향상시키는 표적 지향적이고 효과적인 치료법을 제공함으로써 만성질환 관리를 돕습니다. 예를 들어, 미국 국립의학도서관(National Library of Medicine)의 2024년 6월 추정에 따르면, 2050년까지 50세 이상 미국인 중 적어도 한 가지 이상의 만성질환을 앓고 있는 인구는 약 1억 4,266만 명에 달하고, 99.5% 증가할 것으로 예상하고 있습니다. 증가할 것으로 예측됩니다. 따라서 만성질환의 유병률 증가가 전문의약품 시장의 성장을 견인하고 있습니다.

이 시장의 주요 기업들은 환자 참여도 향상, 치료 순응도 개선, 의료 서비스 제공의 효율성 향상을 위해 통합 디지털 의료 공간과 같은 혁신적인 솔루션에 집중하고 있습니다. 통합 디지털 케어 공간은 환자, 의료진, 지원 서비스를 연결하는 디지털 헬스 기술을 갖춘 가상 또는 물리적 플랫폼으로, 연계 의료와 더 나은 치료 결과를 실현합니다. 예를 들어, 2024년 4월, 미국에 본사를 둔 약국 주도형 헬스케어 기업인 월그린 부츠 얼라이언스(Walgreens Boots Alliance)는 통합형 전문약국 부문 내에서 유전자 및 세포치료 서비스를 시작했습니다. 이러한 노력은 첨단 치료를 지원하고 복잡한 물류 수요에 대응하기 위한 것으로, 전문 의약품 공급 확대에 주력하고 있는 회사의 노력을 반영합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업 및 혁신 기업

제38장 세계 시장 경쟁 벤치마킹과 대시보드

제39장 주요 인수합병(M&A)

제40장 시장 잠재력이 높은 국가, 부문, 전략

제41장 부록

영문목차

Specialty pharmaceuticals refer to a class of medications that are high-cost, complex, and often require special handling, administration, or monitoring. These drugs are typically prescribed for chronic, rare, or complex conditions, including cancer, autoimmune diseases, and rare genetic disorders.

The main drug types of specialty pharmaceuticals include biologics, biosimilars, orphan drugs, small molecules, and others. Biologics are complex medicines derived from living organisms or their components and are used to treat various diseases. These medications can be administered via oral, injectable, intranasal, transdermal, or inhalation routes and are applied across therapeutic areas such as oncology, autoimmune disorders, neurology, infectious diseases, rare genetic disorders, and more. Distribution channels include both online and offline platforms, and the key end users are hospitals, specialty clinics, homecare settings, and pharmacies.

Tariffs have impacted the specialty pharmaceuticals market by increasing the cost of imported biologics, biosimilars, orphan drugs, and advanced drug delivery systems, which has disrupted supply chains and increased treatment costs. Segments like biologics and orphan drugs are most affected, particularly in regions like North America and Europe that rely heavily on imports. On the positive side, tariffs have encouraged domestic manufacturing, innovation in cost-effective therapies, and expansion of local production capabilities, potentially improving accessibility and reducing long-term dependency on imports.

The specialty pharmaceuticals market research report is one of a series of new reports from The Business Research Company that provides specialty pharmaceuticals market statistics, including specialty pharmaceuticals industry global market size, regional shares, competitors with a specialty pharmaceuticals market share, detailed specialty pharmaceuticals market segments, market trends and opportunities, and any further data you may need to thrive in the specialty pharmaceuticals industry. This specialty pharmaceuticals market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The specialty pharmaceuticals market size has grown strongly in recent years. It will grow from $594.05 billion in 2025 to $653.16 billion in 2026 at a compound annual growth rate (CAGR) of 10.0%. The growth in the historic period can be attributed to high cost of specialty pharmaceuticals, limited availability of advanced therapies, growing prevalence of chronic and rare diseases, increasing healthcare infrastructure, rising patient awareness about specialty treatments.

The specialty pharmaceuticals market size is expected to see strong growth in the next few years. It will grow to $943.31 billion in 2030 at a compound annual growth rate (CAGR) of 9.6%. The growth in the forecast period can be attributed to development of cell and gene therapies, expansion of personalized medicine, rising investment in biologics and biosimilars, increasing adoption of advanced drug delivery systems, growth of telehealth and remote patient management. Major trends in the forecast period include rising adoption of biologics and biosimilars in specialty treatments, growth in orphan drugs for rare diseases, increasing use of personalized medicines and advanced drug delivery systems, expansion of homecare and specialty clinics for chronic disease management, integration of telehealth and remote patient monitoring for specialty pharmaceuticals.

The increasing prevalence of chronic diseases is expected to drive the growth of the specialty pharmaceuticals market in the coming years. Chronic diseases are long-term health conditions that typically last a year or more, requiring ongoing medical attention and often limiting daily activities. The rise in chronic disease prevalence is largely attributed to aging populations, as older adults are more prone to conditions such as diabetes, heart disease, and arthritis. Specialty pharmaceuticals aid in managing chronic diseases by providing targeted, high-efficacy therapies that enhance patient outcomes and quality of life, particularly when standard treatments are insufficient. For instance, in June 2024, according to the National Library of Medicine, a US-based medical library, the number of Americans aged 50 and older living with at least one chronic condition is projected to nearly double by 2050, reaching approximately 142.66 million, a 99.5% increase. Therefore, the rising prevalence of chronic diseases is fueling the specialty pharmaceuticals market.

Key companies in this market are focusing on innovative solutions, such as integrated digital care spaces, to enhance patient engagement, improve treatment adherence, and streamline healthcare delivery. Integrated digital care spaces are virtual or physical platforms equipped with digital health technologies that connect patients, providers, and support services, enabling coordinated care and better outcomes. For example, in April 2024, Walgreens Boots Alliance, Inc., a US-based pharmacy-led health company, launched gene and cell services within its integrated specialty pharmacy division. This initiative supports advanced therapies and addresses complex logistical needs, reflecting Walgreens' commitment to expanding its specialty pharmaceuticals offerings.

In December 2023, Pfizer Inc., a US-based pharmaceutical and biotechnology company, acquired Seagen Inc. for $43 billion. This acquisition provides Pfizer access to Seagen's antibody-drug conjugate technologies, marketed oncology therapies, and robust research pipeline, strengthening its cancer treatment capabilities and global oncology presence. Seagen Inc. is a US-based company recognized for its leadership in targeted cancer therapeutics and antibody-drug conjugate development.

Major companies operating in the specialty pharmaceuticals market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., GlaxoSmithKline plc, Gilead Sciences Inc., Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Limited, Bausch Health Companies Inc., Sun Pharmaceutical Industries Limited, Hikma Pharmaceuticals plc, United Therapeutics Corporation, Mallinckrodt plc, Biocon Biologics Limited, Medicure Inc.

North America was the largest region in the specialty pharmaceuticals market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the specialty pharmaceuticals market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the specialty pharmaceuticals market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The specialty pharmaceuticals market consists of sales of personalized medicine, rare disease treatments, and cellular immunotherapies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Specialty Pharmaceuticals Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses specialty pharmaceuticals market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for specialty pharmaceuticals ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The specialty pharmaceuticals market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Drug Types: Biologics; Biosimilars; Orphan Drugs; Small Molecules; Other Drug Types
• 2) By Route Of Administration: Oral; Injectables; Intranasal; Transdermal; Inhalation
• 3) By Therapeutic Area: Oncology; Autoimmune Diseases; Neurology; Infectious Diseases; Rare Genetic Disorders; Other Therapeutic Areas
• 4) By Distribution Channel: Online; Offline
• 5) By End User: Hospitals; Specialty Clinics; Homecare Settings; Pharmacies
• Subsegments:
• 1) By Biologics: Monoclonal Antibodies; Recombinant Proteins; Vaccines; Cell And Gene Therapies; Fusion Proteins
• 2) By Biosimilars: Monoclonal Antibody Biosimilars; Insulin Biosimilars; Growth Hormone Biosimilars; Erythropoietin Biosimilars; Other Biosimilars
• 3) By Orphan Drugs: Rare Genetic Disorders; Rare Cancers; Rare Metabolic Disorders; Rare Infectious Diseases; Rare Autoimmune Diseases
• 4) By Small Molecules: Chemotherapy Agents; Immunosuppressants; Anti-inflammatory Agents; Antiviral Drugs; Hormonal Therapies
• 5) By Other Drug Types: Advanced Drug Delivery Systems; Combination Therapies; Personalized Medicines; Nanomedicines; Radiopharmaceuticals
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Merck & Co. Inc.; AbbVie Inc.; Novartis AG; Sanofi S.A.; GlaxoSmithKline plc; Gilead Sciences Inc.; Amgen Inc.; Viatris Inc.; Teva Pharmaceutical Industries Limited; Bausch Health Companies Inc.; Sun Pharmaceutical Industries Limited; Hikma Pharmaceuticals plc; United Therapeutics Corporation; Mallinckrodt plc; Biocon Biologics Limited; Medicure Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Specialty Pharmaceuticals Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Specialty Pharmaceuticals Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Specialty Pharmaceuticals Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Specialty Pharmaceuticals Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Biotechnology, Genomics & Precision Medicine
  • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.3 Industry 4.0 & Intelligent Manufacturing
  • 4.1.4 Artificial Intelligence & Autonomous Intelligence
  • 4.1.5 Internet of Things (IoT), Smart Infrastructure & Connected Ecosystems
• 4.2. Major Trends
  • 4.2.1 Rising Adoption Of Biologics And Biosimilars In Specialty Treatments
  • 4.2.2 Growth In Orphan Drugs For Rare Diseases
  • 4.2.3 Increasing Use Of Personalized Medicines And Advanced Drug Delivery Systems
  • 4.2.4 Expansion Of Homecare And Specialty Clinics For Chronic Disease Management
  • 4.2.5 Integration Of Telehealth And Remote Patient Monitoring For Specialty Pharmaceuticals

5. Specialty Pharmaceuticals Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Specialty Clinics
• 5.3 Homecare Settings
• 5.4 Pharmacies
• 5.5 Research & Diagnostic Centers

6. Specialty Pharmaceuticals Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Specialty Pharmaceuticals Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Specialty Pharmaceuticals PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Specialty Pharmaceuticals Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Specialty Pharmaceuticals Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Specialty Pharmaceuticals Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Specialty Pharmaceuticals Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Specialty Pharmaceuticals Market Segmentation

• 9.1. Global Specialty Pharmaceuticals Market, Segmentation By Drug Types, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Biologics, Biosimilars, Orphan Drugs, Small Molecules, Other Drug Types
• 9.2. Global Specialty Pharmaceuticals Market, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oral, Injectables, Intranasal, Transdermal, Inhalation
• 9.3. Global Specialty Pharmaceuticals Market, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Oncology, Autoimmune Diseases, Neurology, Infectious Diseases, Rare Genetic Disorders, Other Therapeutic Areas
• 9.4. Global Specialty Pharmaceuticals Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Online, Offline
• 9.5. Global Specialty Pharmaceuticals Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Specialty Clinics, Homecare Settings, Pharmacies
• 9.6. Global Specialty Pharmaceuticals Market, Sub-Segmentation Of Biologics, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Monoclonal Antibodies, Recombinant Proteins, Vaccines, Cell And Gene Therapies, Fusion Proteins
• 9.7. Global Specialty Pharmaceuticals Market, Sub-Segmentation Of Biosimilars, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Monoclonal Antibody Biosimilars, Insulin Biosimilars, Growth Hormone Biosimilars, Erythropoietin Biosimilars, Other Biosimilars
• 9.8. Global Specialty Pharmaceuticals Market, Sub-Segmentation Of Orphan Drugs, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Rare Genetic Disorders, Rare Cancers, Rare Metabolic Disorders, Rare Infectious Diseases, Rare Autoimmune Diseases
• 9.9. Global Specialty Pharmaceuticals Market, Sub-Segmentation Of Small Molecules, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Chemotherapy Agents, Immunosuppressants, Anti-inflammatory Agents, Antiviral Drugs, Hormonal Therapies
• 9.10. Global Specialty Pharmaceuticals Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Advanced Drug Delivery Systems, Combination Therapies, Personalized Medicines, Nanomedicines, Radiopharmaceuticals

10. Specialty Pharmaceuticals Market Regional And Country Analysis

• 10.1. Global Specialty Pharmaceuticals Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Specialty Pharmaceuticals Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Specialty Pharmaceuticals Market

• 11.1. Asia-Pacific Specialty Pharmaceuticals Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Specialty Pharmaceuticals Market, Segmentation By Drug Types, Segmentation By Route Of Administration, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Specialty Pharmaceuticals Market

• 12.1. China Specialty Pharmaceuticals Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Specialty Pharmaceuticals Market, Segmentation By Drug Types, Segmentation By Route Of Administration, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Specialty Pharmaceuticals Market

• 13.1. India Specialty Pharmaceuticals Market, Segmentation By Drug Types, Segmentation By Route Of Administration, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Specialty Pharmaceuticals Market

• 14.1. Japan Specialty Pharmaceuticals Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Specialty Pharmaceuticals Market, Segmentation By Drug Types, Segmentation By Route Of Administration, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Specialty Pharmaceuticals Market

• 15.1. Australia Specialty Pharmaceuticals Market, Segmentation By Drug Types, Segmentation By Route Of Administration, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Specialty Pharmaceuticals Market

• 16.1. Indonesia Specialty Pharmaceuticals Market, Segmentation By Drug Types, Segmentation By Route Of Administration, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Specialty Pharmaceuticals Market

• 17.1. South Korea Specialty Pharmaceuticals Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Specialty Pharmaceuticals Market, Segmentation By Drug Types, Segmentation By Route Of Administration, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Specialty Pharmaceuticals Market

• 18.1. Taiwan Specialty Pharmaceuticals Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Specialty Pharmaceuticals Market, Segmentation By Drug Types, Segmentation By Route Of Administration, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Specialty Pharmaceuticals Market

• 19.1. South East Asia Specialty Pharmaceuticals Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Specialty Pharmaceuticals Market, Segmentation By Drug Types, Segmentation By Route Of Administration, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Specialty Pharmaceuticals Market

• 20.1. Western Europe Specialty Pharmaceuticals Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Specialty Pharmaceuticals Market, Segmentation By Drug Types, Segmentation By Route Of Administration, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Specialty Pharmaceuticals Market

• 21.1. UK Specialty Pharmaceuticals Market, Segmentation By Drug Types, Segmentation By Route Of Administration, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Specialty Pharmaceuticals Market

• 22.1. Germany Specialty Pharmaceuticals Market, Segmentation By Drug Types, Segmentation By Route Of Administration, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Specialty Pharmaceuticals Market

• 23.1. France Specialty Pharmaceuticals Market, Segmentation By Drug Types, Segmentation By Route Of Administration, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Specialty Pharmaceuticals Market

• 24.1. Italy Specialty Pharmaceuticals Market, Segmentation By Drug Types, Segmentation By Route Of Administration, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Specialty Pharmaceuticals Market

• 25.1. Spain Specialty Pharmaceuticals Market, Segmentation By Drug Types, Segmentation By Route Of Administration, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Specialty Pharmaceuticals Market

• 26.1. Eastern Europe Specialty Pharmaceuticals Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Specialty Pharmaceuticals Market, Segmentation By Drug Types, Segmentation By Route Of Administration, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Specialty Pharmaceuticals Market

• 27.1. Russia Specialty Pharmaceuticals Market, Segmentation By Drug Types, Segmentation By Route Of Administration, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Specialty Pharmaceuticals Market

• 28.1. North America Specialty Pharmaceuticals Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Specialty Pharmaceuticals Market, Segmentation By Drug Types, Segmentation By Route Of Administration, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Specialty Pharmaceuticals Market

• 29.1. USA Specialty Pharmaceuticals Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Specialty Pharmaceuticals Market, Segmentation By Drug Types, Segmentation By Route Of Administration, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Specialty Pharmaceuticals Market

• 30.1. Canada Specialty Pharmaceuticals Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Specialty Pharmaceuticals Market, Segmentation By Drug Types, Segmentation By Route Of Administration, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Specialty Pharmaceuticals Market

• 31.1. South America Specialty Pharmaceuticals Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Specialty Pharmaceuticals Market, Segmentation By Drug Types, Segmentation By Route Of Administration, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Specialty Pharmaceuticals Market

• 32.1. Brazil Specialty Pharmaceuticals Market, Segmentation By Drug Types, Segmentation By Route Of Administration, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Specialty Pharmaceuticals Market

• 33.1. Middle East Specialty Pharmaceuticals Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Specialty Pharmaceuticals Market, Segmentation By Drug Types, Segmentation By Route Of Administration, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Specialty Pharmaceuticals Market

• 34.1. Africa Specialty Pharmaceuticals Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Specialty Pharmaceuticals Market, Segmentation By Drug Types, Segmentation By Route Of Administration, Segmentation By Therapeutic Area, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Specialty Pharmaceuticals Market Regulatory and Investment Landscape

36. Specialty Pharmaceuticals Market Competitive Landscape And Company Profiles

• 36.1. Specialty Pharmaceuticals Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Specialty Pharmaceuticals Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Specialty Pharmaceuticals Market Company Profiles
  • 36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

37. Specialty Pharmaceuticals Market Other Major And Innovative Companies

• Sanofi S.A., GlaxoSmithKline plc, Gilead Sciences Inc., Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Limited, Bausch Health Companies Inc., Sun Pharmaceutical Industries Limited, Hikma Pharmaceuticals plc, United Therapeutics Corporation, Mallinckrodt plc, Biocon Biologics Limited, Medicure Inc.

38. Global Specialty Pharmaceuticals Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Specialty Pharmaceuticals Market

40. Specialty Pharmaceuticals Market High Potential Countries, Segments and Strategies

• 40.1 Specialty Pharmaceuticals Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Specialty Pharmaceuticals Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Specialty Pharmaceuticals Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer